Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma-Reference-Cited by-同舟云学术

Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma

Published:2021-10 Issue:30 Volume:17 Page:3965-3976
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Metzenmacher Martin¹^ORCID,Rizzo Filippo²,Kambartel Kato³,Panse Jens⁴^ORCID,Schaufler Diana⁵,Scheffler Matthias⁵,Azeh Ivo⁶,Hoiczyk Mathias⁷^ORCID,Turki Amin T¹⁸,Atz Judith⁹,Buchner Hannes¹⁰,Hoffmann Christopher⁹^ORCID,C Christoph Daniel²^ORCID

Affiliation:

1. Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstrasse 55, Essen 45122, Germany

2. Department of Medical Oncology/Hematology, Evang, Kliniken Essen-Mitte, Essen, Germany

3. Department of Pneumology & Allergy, Lung Cancer Center, Bethanien Hospital Moers, Germany

4. Department of Oncology, Haematology, Haemostaseology & Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany

5. University of Cologne, Faculty of Medicine & University Hospital of Cologne; Department I of Internal Medicine, Center for Integrated Oncology, Aachen Bonn Cologne Dusseldorf; Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany

6. Onkologische Gemeinschaftspraxis und Tagesklinik, Gelsenkirchen, Germany

7. Department of Gastroenterology, Hematology, Oncology, Diabetology & Rheumatology, Marien-Hospital Wesel, Pastor-Janßen-Straße 8-38, Wesel 46483, Germany

8. Department of Hematology & Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, Essen 45122, Germany

9. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

10. Staburo GmbH, Munich, Germany

Abstract

Aim: This real-world analysis evaluated docetaxel plus nintedanib in patients with advanced pulmonary adenocarcinoma after chemotherapy and immune checkpoint inhibitor failure, for whom treatment options are limited. Methods: Data were sourced retrospectively from seven German centers. Results: Of 93 patients, overall response rate was 41.4% (disease control rate: 75.9%). Of 57 patients given third-line docetaxel plus nintedanib, overall response rate was 50.0% (disease control rate: 82.7%). Median overall survival following third-line docetaxel plus nintedanib was 8.4 months. Adverse events were consistent with the known safety profile of docetaxel plus nintedanib. Conclusion: To date, this was the largest retrospective, real-world analysis of docetaxel plus nintedanib after chemotherapy–immunotherapy failure, indicating that docetaxel plus nintedanib offers meaningful clinical benefits in this setting.

Funder

Boehringer Ingelheim

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-0424

Reference28 articles.

1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

3. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC